此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)

2020年3月13日 更新者:University Hospital, Clermont-Ferrand

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise

The high prevalence of childhood obesity is a major public health issue, worldwide. Childhood obesity is associated with a high risk of cardiovascular events in adulthood, but recent studies also point out the development of cardiovascular complications in childhood or adolescence justifying the need for early detection and appropriate therapeutic management to prevent the development of more severe abnormalities. This project proposes to evaluate the myocardial function in a fine and comprehensive way (longitudinal, circumferential and radial linear deformations, and rotation / torsion mechanics) from the deformation imaging (MRI and high-resolution echocardiography), in obese adolescents following a lifestyle intervention combining diet and physical activity.

研究概览

详细说明

The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.

In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).

Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.

Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.

研究类型

介入性

注册 (预期的)

50

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Clermont-Ferrand、法国、63000
        • CHU de Clermont-Ferrand

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

12年 至 16年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • age between 12 and 16 years old
  • mature (menarche)
  • suitable for physical activity
  • able to give an informative consent
  • affiliated at French insurance company
  • consent from the legal representatives
  • For obese adolescents: BMI greater than the 97th percentile of national curves.
  • For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Exclusion Criteria:

  • Medical or surgical history judged by the investigator as incompatible with the study
  • Drugs that may interfere with the study results
  • Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
  • Smoking
  • Alcohol consumption
  • Intense physical activity in competition

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Obese adolescents
BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention

Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

无干预:Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
cardiac ectopic fat deposits
大体时间:Month 3
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Month 3
cardiac ectopic fat deposits
大体时间:Day 0
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Day 0
cardiac ectopic fat deposits
大体时间:Day 0
Quantification of cardiac ectopic fat deposits (volume using MRI)
Day 0
cardiac ectopic fat deposits
大体时间:Month 3
Quantification of cardiac ectopic fat deposits (volume using MRI)
Month 3
cardiac ectopic fat deposits
大体时间:Month 3
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Month 3
cardiac ectopic fat deposits
大体时间:Day 0
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Day 0
left myocardial regional function
大体时间:Month 3
left myocardial regional function (echocardiography)
Month 3
left myocardial regional function
大体时间:Month 3
left myocardial regional function (MRI)
Month 3
left myocardial regional function
大体时间:Day 0
left myocardial regional function (echocardiography)
Day 0
left myocardial regional function
大体时间:Day 0
left myocardial regional function (MRI)
Day 0

次要结果测量

结果测量
措施说明
大体时间
macrovascularisation
大体时间:Day 0
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Day 0
macrovascularisation
大体时间:Month 3
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Month 3
microvascularisation
大体时间:Month 3
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Month 3
microvascularisation
大体时间:Day 0
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Day 0
microvascularisation
大体时间:Day 0
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Day 0
microvascularisation
大体时间:Month 3
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Month 3
microvascularisation
大体时间:Month 3
measure of microvascular perfusion using Iontophoresis procedure
Month 3
microvascularisation
大体时间:Day 0
measure of microvascular perfusion using Iontophoresis procedure
Day 0
microvascularisation
大体时间:Day 0
measure of microvascular perfusion using flowmotion
Day 0
microvascularisation
大体时间:Month 3
measure of microvascular perfusion using flowmotion
Month 3
heart rate variability
大体时间:Month 3
measure of heart rate variability using a holter
Month 3
heart rate variability
大体时间:Day 0
measure of heart rate variability using a holter
Day 0
skin conductance
大体时间:Day 0
measure of skin conductance using Wristband electrodes - Empatica E4
Day 0
skin conductance
大体时间:Month 3
measure of skin conductance using Wristband electrodes - Empatica E4
Month 3
Liver steatosis
大体时间:Month 3
measure of liver steatosis by MRI
Month 3
Liver steatosis
大体时间:Day 0
measure of liver steatosis by MRI
Day 0
Liver steatosis
大体时间:Day 0
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Day 0
Liver steatosis
大体时间:Month 3
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Month 3
Liver steatosis
大体时间:month 3
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
month 3
Liver steatosis
大体时间:Day 0
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
Day 0
Liver fibrosis
大体时间:Day 0
measure of liver fibrosis by fibroscanner (liver stiffness)
Day 0
Liver fibrosis
大体时间:Month 3
measure of liver fibrosis by fibroscanner (liver stiffness)
Month 3
Liver fibrosis
大体时间:Month 3
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Month 3
Liver fibrosis
大体时间:Day 0
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Day 0
blood pressure
大体时间:Day0
measure of blood pressure using sphygmomanometer
Day0
blood pressure
大体时间:month 3
measure of blood pressure using sphygmomanometer
month 3
Fitness
大体时间:Month 3
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Month 3
Fitness
大体时间:Day 0
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Day 0
muscle mass
大体时间:Month 3
measure of muscle mass using impedancemeter
Month 3
fat mass
大体时间:Month 3
measure of muscle mass using impedancemeter
Month 3
bone structure
大体时间:Month 3
measure of muscle mass using impedancemeter
Month 3
muscle mass
大体时间:Day 0
measure of muscle mass using impedancemeter
Day 0
fat mass
大体时间:Day 0
measure of muscle mass using impedancemeter
Day 0
bone structure
大体时间:Day 0
measure of muscle mass using impedancemeter
Day 0
muscle mass
大体时间:Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
fat mass
大体时间:Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
bone structure
大体时间:Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
muscle mass
大体时间:Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
fat mass
大体时间:Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
bone structure
大体时间:Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
muscle mass
大体时间:Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
fat mass
大体时间:Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
bone structure
大体时间:Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
muscle mass
大体时间:Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
fat mass
大体时间:Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
bone structure
大体时间:Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
muscle mass
大体时间:Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
fat mass
大体时间:Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
bone structure
大体时间:Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
muscle mass
大体时间:Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
fat mass
大体时间:Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
bone structure
大体时间:Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
depression
大体时间:Day 0
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Day 0
depression
大体时间:Month 3
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Month 3
anxiety
大体时间:Day 0
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Day 0
anxiety
大体时间:Month 3
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Month 3
General health
大体时间:Day 0
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Day 0
General health
大体时间:Month 3
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Month 3
Stress
大体时间:day 0
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
day 0
Stress
大体时间:Month 3
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Fatigue
大体时间:Day 0
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Day 0
Fatigue
大体时间:Month 3
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Sleep
大体时间:day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Sleep
大体时间:Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Burnout
大体时间:day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Burnout
大体时间:Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Mindfulness
大体时间:Day 0
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Day 0
Mindfulness
大体时间:Month 3
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Month 3
Coping
大体时间:Day 0
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Day 0
Coping
大体时间:Month 3
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Month 3
Emotions
大体时间:Day 0
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Day 0
Emotions
大体时间:Month 3
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Month 3
Perception of work
大体时间:Day 0
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Day 0
Perception of work
大体时间:Month 3
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Month 3
Self-efficacy
大体时间:Day 0
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Day 0
Self-efficacy
大体时间:Month 3
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Month 3
Alexithymia
大体时间:Day 0
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Day 0
Alexithymia
大体时间:Month 3
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Month 3
Illness perception
大体时间:Day 0
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Day 0
Illness perception
大体时间:Month 3
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Month 3
Metacognition
大体时间:Day 0
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Day 0
Metacognition
大体时间:Month 3
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Month 3
Time perception
大体时间:Day 0
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Day 0
Time perception
大体时间:Month 3
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Month 3
Physical activity
大体时间:Day 0
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Day 0
Physical activity
大体时间:Month 3
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Month 3
Life style
大体时间:Day 0
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Day 0
Life style
大体时间:Month 3
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Month 3
cholesterol
大体时间:Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
triglycerides
大体时间:Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
cholesterol
大体时间:Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
triglycerides
大体时间:Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
Cortisol
大体时间:Day 0
hormone measure by blood analyses to evaluate alloplastic load
Day 0
Cortisol
大体时间:Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
DHEAS
大体时间:day 0
hormone measure by blood analyses to evaluate alloplastic load
day 0
DHEAS
大体时间:Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
BDNF
大体时间:Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
BDNF
大体时间:Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
CRP
大体时间:Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
pro-inflammatory cytokines
大体时间:Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
TNF alpha
大体时间:Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
CRP
大体时间:Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
pro-inflammatory cytokines
大体时间:Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
TNF alpha
大体时间:Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
大体时间:Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
大体时间:Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
Leptin
大体时间:Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Leptin
大体时间:Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
Ghrelin
大体时间:Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Ghrelin
大体时间:Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
NPY
大体时间:day 0
measure by blood analyses to evaluate appetite regulation
day 0
NPY
大体时间:Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
adiponectine
大体时间:Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
adiponectine
大体时间:Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
CCK
大体时间:Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Month 3
大体时间:Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Insulin
大体时间:Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
Insulin
大体时间:Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
HbA1c
大体时间:Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
HbA1c
大体时间:Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
glucose
大体时间:Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
glucose
大体时间:Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
Albumin
大体时间:Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
Albumin
大体时间:Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
transthyretin
大体时间:Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
transthyretin
大体时间:Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
Homeostasis
大体时间:Day 0
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Day 0
Homeostasis
大体时间:Month 3
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Month 3
Osteoresorption
大体时间:Day 0
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Day 0
Osteoresorption
大体时间:Month 3
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Month 3
Osteoformation
大体时间:Day 0
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Day 0
Osteoformation
大体时间:Month 3
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Month 3
VEGF
大体时间:Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
VEGF
大体时间:Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
PAI1
大体时间:Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
PAI1
大体时间:Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
weight
大体时间:Day 0
measure of weight in kilograms
Day 0
weight
大体时间:Month 3
measure of weight in kilograms
Month 3
waist circumference
大体时间:Day 0
measure of waist circumference in centimetres
Day 0
waist circumference
大体时间:Month 3
measure of waist circumference in centimetres
Month 3

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2020年9月1日

初级完成 (预期的)

2021年6月1日

研究完成 (预期的)

2021年6月1日

研究注册日期

首次提交

2020年2月10日

首先提交符合 QC 标准的

2020年3月13日

首次发布 (实际的)

2020年3月17日

研究记录更新

最后更新发布 (实际的)

2020年3月17日

上次提交的符合 QC 标准的更新

2020年3月13日

最后验证

2020年2月1日

更多信息

与本研究相关的术语

其他研究编号

  • RBHP 2019 DUTHEIL
  • 2019-A01804-53 (其他标识符:ANSM)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅